F2G Overview
Key information, insights, contact details, and team at F2G.
F2G is advancing its own patented compounds and technologies which will lead to the development of novel agents to treat serious fungal disease. The Company was founded on its proprietary genomics technology (MycoBank®) that identifies essential gene targets in fungi. Having received initial funding in 2002 the company then rapidly diversifiedinto chemistry-driven discovery.
$100M
Latest Funding
Series H
Latest Funding Stage
2024-09-13
Funding Date
95
Employees
United Kingdom
Location
Manchester, Manchester
City & State
Open Positions
View Careers PageHiring For
Investment Thesis
No thesis information available yet.
Key Contacts
Team Members
( total contacts)Founding Story
No founding story information available yet.
Product
No product analysis information available yet.
Market
No market analysis information available yet.
Competition
No competitive analysis information available yet.
Business Model
No business model analysis information available yet.
Similar Companies
Overture Life
Overture Life is a biotechnology company that develops automated technologies for assisted reproductive procedures, aiming to enhance the efficiency and accessibility of in vitro fertilization (IVF). Its solutions focus on automating complex embryology lab processes, such as egg vitrification and embryo warming, to improve consistency and reducecosts.
TadHealth
TadHealth offers a school-based EHR and health management product with essential modules for running clinics and staff health operations, enabling public sector institutions to seamlessly transition between billable processes and active resources within communities.
Araceli Biosciences
Araceli Biosciences is a developer of scientific tools for tissue- and cell-based biomarker discovery, drug discovery, and drug development. The company focuses on developing scientific instruments to improve outcomes and enable customers to advance scientific and medical research.
Granite Bio
Granite Bio specializes in the development of therapeutic antibodies for the treatment of inflammatory, autoimmune, and fibrotic diseases, enabling companies to support in the areas of biotechnology, pharmaceuticals, diagnostics, and other areas of life sciences.
Traction
No traction analysis information available yet.
Valuation
No valuation analysis information available yet.
Key Opportunities
No key opportunities information available yet.
Key Risks
No key risks information available yet.